Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Division of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Radiat Oncol. 2018 Feb 9;13(1):23. doi: 10.1186/s13014-018-0966-5.
The purpose of this study was to perform a dosimetric comparison between proton beam therapy (PBT) and photon radiation therapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who were treated with PBT in our institution. In addition, we evaluated the correlation between toxicities and dosimetric parameters, especially the doses to normal lung or heart tissue, to clarify the clinical advantage of PBT over photon radiation therapy.
A total of 37 consecutive patients with Stage III thoracic ESCC who had received PBT with or without concurrent chemotherapy between October 2012 and December 2015 were evaluated in this study. The dose distributions of PBT were compared with those of dummy 3-dimensional conformal radiation therapy (3DCRT) and Intensity Modulated Radiation Therapy (IMRT), focusing especially on the doses to organs at risk, such as normal lung and heart tissue.
Of the 37 patients, the data from 27 patients were analyzed. Among these 27 patients, four patients (15%) developed grade 2 pericardial effusion as a late toxicity. None of the patients developed grade 3 or worse acute or late pulmonary and cardiac toxicities. When the dosimetric parameters between PBT and planned 3DCRT were compared, all the PBT domestic variables for the lung dose except for lung V10 GyE and V15 GyE were significantly lower than those for the dummy 3DCRT plans, and the PBT domestic variables for the heart dose were also significantly lower than those for the dummy 3DCRT plans. When the PBT and IMRT plans were compared, all the PBT domestic variables for the doses to the lung and heart were significantly lower than those for the dummy IMRT plans. Regarding the correlation between the grades of toxicities and the dosimetric parameters, no significant correlation was seen between the occurrence of grade 2 pericardial effusion and the dose to the heart.
When the dosimetric parameters of the dose distributions for the treatment of patients with locally advanced stage III ESCC were compared between PBT and 3DCRT or IMRT, PBT enabled a significant reduction in the dose to the lung and heart, compared with 3DCRT or IMRT.
本研究旨在对我院接受质子束治疗(PBT)的局部晚期食管鳞状细胞癌(ESCC)患者的 PBT 与光子放射治疗进行剂量学比较。此外,我们还评估了毒性与剂量学参数之间的相关性,尤其是正常肺或心脏组织的剂量,以明确 PBT 相对于光子放射治疗的临床优势。
本研究共评估了 37 例 2012 年 10 月至 2015 年 12 月期间接受 PBT 联合或不联合同期化疗的 III 期胸段 ESCC 患者。比较了 PBT 的剂量分布与虚拟三维适形放疗(3DCRT)和调强放疗(IMRT)的剂量分布,重点关注如正常肺和心脏组织等危及器官的剂量。
在这 37 例患者中,27 例患者的数据被分析。在这 27 例患者中,有 4 例(15%)发生晚期毒性的 2 级心包积液。没有患者发生 3 级或更高级别的急性或晚期肺和心脏毒性。当比较 PBT 与计划 3DCRT 的剂量学参数时,除了肺 V10 GyE 和 V15 GyE 外,所有 PBT 的肺剂量国内变量均显著低于虚拟 3DCRT 计划,而心脏剂量国内变量也显著低于虚拟 3DCRT 计划。当比较 PBT 和 IMRT 计划时,所有 PBT 的肺和心脏剂量国内变量均显著低于虚拟 IMRT 计划。关于毒性程度与剂量学参数之间的相关性,2 级心包积液的发生与心脏剂量之间没有显著相关性。
当比较局部晚期 III 期 ESCC 患者的 PBT 和 3DCRT 或 IMRT 治疗的剂量分布剂量学参数时,与 3DCRT 或 IMRT 相比,PBT 可显著降低肺和心脏的剂量。